{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:28:47Z","timestamp":1789579727991,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blood-based biomarkers are increasingly used to support the identification of Alzheimer\u2019s disease (AD) in clinical and research settings. However, variability between analytical platforms limits their interchangeability and may affect their clinical interpretation. Direct head-to-head comparisons across assays and their alignment with clinical phenotypes remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the inter-test agreement of blood-based biomarkers measured using Roche and Fujirebio assays and to determine which biomarker shows the most robust analytical concordance and clinical relevance in AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants with AD (n\u2009=\u200986) and cognitively healthy controls (HC; n\u2009=\u200956)\u00a0underwent blood biomarker assessment using Roche and Fujirebio platforms.\u00a0Plasma phosphorylated tau at threonine 217 (pTau217), plasma phosphorylated tau at threonine 181 (pTau181), Amyloid-\u03b242 (A\u03b242), amyloid-\u03b240 (A\u03b240), and the amyloid-\u03b242\/amyloid-\u03b240 ratio (A\u03b242\/A\u03b240) and glial fibrillary acidic protein (GFAP) were analyzed. Inter-test agreement was assessed using intraclass correlation coefficients, concordance analyses, and regression-based methods. Clinical relevance was evaluated by association with measures of cognitive and functional impairment evaluated using the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating Scale \u2013 Sum of Boxes (CDR-SB). Analyses were adjusted for age and sex and complemented by sensitivity and stability analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Inter-test agreement varied across biomarkers, with pTau217 demonstrating the highest and most stable concordance between Roche and Fujirebio assays. Among the evaluated markers, pTau217 also showed the strongest and most consistent associations with global cognition measures across diagnostic groups and best discriminated between individuals with AD and HC. GFAP demonstrated robust inter-test agreement but weaker alignment with clinical measures, while amyloid-based markers showed lower concordance and greater variability across platforms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Head-to-head comparison of Roche and Fujirebio assays revealed biomarker-specific differences in inter-test agreement, limiting the direct interchangeability of measurements across platforms. Plasma pTau217 showed the most consistent analytical concordance and clinical associations in this setting, supporting its potential utility in cross-platform applications. However, these findings also highlight the need for assay-specific calibration and cautious interpretation of biomarker thresholds in clinical and research use and the need for further validation across diverse populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT05059158, NCT05317871<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40520-026-03420-5","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:55:59Z","timestamp":1782395759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-6240","authenticated-orcid":false,"given":"Carolin","family":"Kurz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hattenkofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Pihale-Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hufnagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim \u00dcst\u00fcn","family":"G\u00fcrsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris-Stephan","family":"Rauchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"3420_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105405","volume":"109","author":"A Feizpour","year":"2024","unstructured":"Feizpour A, Doecke JD, Dore V et al (2024) Detection and staging of Alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform. EBioMedicine 109:105405. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105405","journal-title":"EBioMedicine"},{"key":"3420_CR2","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1002\/alz.14140","volume":"20","author":"DJ Figdore","year":"2024","unstructured":"Figdore DJ, Griswold M, Bornhorst JA et al (2024) Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays. Alzheimers Dement 20:6506\u20136516. https:\/\/doi.org\/10.1002\/alz.14140","journal-title":"Alzheimers Dement"},{"key":"3420_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S et al (2020) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26:379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"key":"3420_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110330","volume":"26","author":"KY Kim","year":"2025","unstructured":"Kim KY, Shin KY, Chang KA (2025) Blood-based Tau as a biomarker for early detection and monitoring of Alzheimer\u2019s disease: a systematic review and meta-analysis. Int J Mol Sci 26:20251023. https:\/\/doi.org\/10.3390\/ijms262110330","journal-title":"Int J Mol Sci"},{"key":"3420_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70828","volume":"21","author":"S Pahlke","year":"2025","unstructured":"Pahlke S, Kahale LA, Mahinrad S et al (2025) Blood-based biomarkers for detecting Alzheimer\u2019s disease pathology in cognitively impaired individuals within specialized care settings: a systematic review and meta-analysis. Alzheimers Dement 21:e70828. https:\/\/doi.org\/10.1002\/alz.70828","journal-title":"Alzheimers Dement"},{"key":"3420_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70535","volume":"21","author":"S Palmqvist","year":"2025","unstructured":"Palmqvist S, Whitson HE, Allen LA et al (2025) Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings. Alzheimers Dement 21:e70535. https:\/\/doi.org\/10.1002\/alz.70535","journal-title":"Alzheimers Dement"},{"key":"3420_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S et al (2024) Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat Rev Neurol 20:269\u2013287. https:\/\/doi.org\/10.1038\/s41582-024-00955-x","journal-title":"Nat Rev Neurol"},{"key":"3420_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae396","volume":"6","author":"F Leipp","year":"2024","unstructured":"Leipp F, Vialaret J, Mohaupt P et al (2024) Glial fibrillary acidic protein in Alzheimer\u2019s disease: a narrative review. Brain Commun 6:fcae396. https:\/\/doi.org\/10.1093\/braincomms\/fcae396","journal-title":"Brain Commun"},{"key":"3420_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H et al (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer Disease. JAMA Neurol 74:557\u2013566. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6117","journal-title":"JAMA Neurol"},{"key":"3420_CR10","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ et al (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146:1592\u20131601. https:\/\/doi.org\/10.1093\/brain\/awac333","journal-title":"Brain"},{"key":"3420_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"3420_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.07.003","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC et al (2015) The centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003","journal-title":"Alzheimers Dement"},{"key":"3420_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189\u2013198. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6","journal-title":"J Psychiatr Res"},{"key":"3420_CR14","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurol 43:2412\u20132414. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a","journal-title":"Neurol"},{"key":"3420_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.120014","author":"G Musso","year":"2025","unstructured":"Musso G, Gabelli C, Puthenparampil M et al (2025) Blood biomarkers for Alzheimer\u2019s disease with the Lumipulse automated platform: Age-effect and clinical value interpretation. Clin Chim Acta. https:\/\/doi.org\/10.1016\/j.cca.2024.120014","journal-title":"Clin Chim Acta"},{"key":"3420_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13687","author":"G Bellomo","year":"2024","unstructured":"Bellomo G, Bayoumy S, Megaro A et al (2024) Fully automated measurement of plasma Abeta42\/40 and p-tau181: analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer\u2019s disease continuum in two independent cohorts. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13687","journal-title":"Alzheimers Dement"},{"key":"3420_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26465","author":"BS Rauchmann","year":"2022","unstructured":"Rauchmann BS, Brendel M, Franzmeier N et al (2022) Microglial activation and connectivity in Alzheimer disease and aging. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.26465","journal-title":"Ann Neurol"},{"key":"3420_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-025-02013-z","author":"C Kurz","year":"2025","unstructured":"Kurz C, Carli L, Gursel SU et al (2025) Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer\u2019s disease and corticobasal syndrome. Eur Arch Psychiatry Clin Neurosci. https:\/\/doi.org\/10.1007\/s00406-025-02013-z","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3420_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02869-z","author":"NR Barthelemy","year":"2024","unstructured":"Barthelemy NR, Salvado G, Schindler SE et al (2024) Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. https:\/\/doi.org\/10.1038\/s41591-024-02869-z","journal-title":"Nat Med"},{"key":"3420_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00665-2","author":"TK Karikari","year":"2022","unstructured":"Karikari TK, Ashton NJ, Brinkmalm G et al (2022) Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. https:\/\/doi.org\/10.1038\/s41582-022-00665-2","journal-title":"Nat Rev Neurol"},{"key":"3420_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12801","author":"C Rabe","year":"2023","unstructured":"Rabe C, Bittner T, Jethwa A et al (2023) Clinical performance and robustness evaluation of plasma amyloid-beta(42\/40) prescreening. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12801","journal-title":"Alzheimers Dement"},{"key":"3420_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15757","author":"C Kurz","year":"2023","unstructured":"Kurz C, Stockl L, Schrurs I et al (2023) Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer\u2019s disease. J Neurochem. https:\/\/doi.org\/10.1111\/jnc.15757","journal-title":"J Neurochem"},{"key":"3420_CR23","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H et al (2021) Head-to-head comparison of 8 plasma Amyloid-beta 42\/40 assays in Alzheimer Disease. JAMA Neurol 78:1375\u20131382. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3180","journal-title":"JAMA Neurol"},{"key":"3420_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00728-w","author":"S De Meyer","year":"2020","unstructured":"De Meyer S, Schaeverbeke JM, Verberk IMW et al (2020) Comparison of ELISA- and SIMOA-based quantification of plasma Abeta ratios for early detection of cerebral amyloidosis. Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/s13195-020-00728-w","journal-title":"Alzheimers Res Ther"},{"key":"3420_CR25","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N et al (2023) Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement 19:1403\u20131414. https:\/\/doi.org\/10.1002\/alz.12787","journal-title":"Alzheimers Dement"},{"key":"3420_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66195-7","volume":"14","author":"W Li","year":"2024","unstructured":"Li W, Sun L, Yue L et al (2024) Diagnostic and predictive power of plasma proteins in Alzheimer\u2019s disease: a cross-sectional and longitudinal study in China. Sci Rep 14:17557. https:\/\/doi.org\/10.1038\/s41598-024-66195-7","journal-title":"Sci Rep"},{"key":"3420_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","volume":"143","author":"DS Smirnov","year":"2022","unstructured":"Smirnov DS, Ashton NJ, Blennow K et al (2022) Plasma biomarkers for Alzheimer\u2019s disease in relation to neuropathology and cognitive change. Acta Neuropathol 143:487\u2013503. https:\/\/doi.org\/10.1007\/s00401-022-02408-5","journal-title":"Acta Neuropathol"},{"key":"3420_CR28","unstructured":"Kurz C, Tegethoff P, Hufnagel A, Perneczky, R. (2025) Validating plasma phosphorylated tau217 for clinical rule-out of cerebral amyloid pathology: evidence from a memory clinic cohort. Journal of Alzheimer\u00b4s Disease, under submission"},{"key":"3420_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71009","volume":"22","author":"DP Hibar","year":"2026","unstructured":"Hibar DP, Bauer A, Rabe C et al (2026) Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts. Alzheimers Dement 22:e71009. https:\/\/doi.org\/10.1002\/alz.71009","journal-title":"Alzheimers Dement"},{"key":"3420_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.06.2266","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG et al (2017) Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2266","journal-title":"Alzheimers Dement"},{"key":"3420_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.010","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E et al (2018) CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.010","journal-title":"Alzheimers Dement"},{"key":"3420_CR32","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1002\/alz.14184","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke MM, Anderson M, Ashford JW et al (2024) Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement 20:8216\u20138224. https:\/\/doi.org\/10.1002\/alz.14184","journal-title":"Alzheimers Dement"},{"key":"3420_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70207","volume":"17","author":"R Perneczky","year":"2025","unstructured":"Perneczky R, Quevenco FC, Hendrix J et al (2025) How can Alzheimer\u2019s disease blood-based biomarkers reach clinical practice? Alzheimers Dement Diagn Assess Dis Monit 17:e70207. https:\/\/doi.org\/10.1002\/dad2.70207","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"3420_CR34","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Petersen KK, Saef B et al (2024) Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimers Dement 20:8074\u20138096. https:\/\/doi.org\/10.1002\/alz.14315","journal-title":"Alzheimers Dement"},{"key":"3420_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/alz.12433","volume":"18","author":"S Franzen","year":"2022","unstructured":"Franzen S, Smith JE, van den Berg E et al (2022) Diversity in Alzheimer\u2019s disease drug trials: the importance of eligibility criteria. Alzheimers Dement 18:810\u2013823. https:\/\/doi.org\/10.1002\/alz.12433","journal-title":"Alzheimers Dement"},{"key":"3420_CR36","doi-asserted-by":"publisher","first-page":"20150501","DOI":"10.1371\/journal.pone.0124500","volume":"10","author":"A Leinonen","year":"2015","unstructured":"Leinonen A, Koponen M, Hartikainen S (2015) Systematic review: representativeness of participants in RCTs of Acetylcholinesterase Inhibitors. PLoS ONE 10:20150501. https:\/\/doi.org\/10.1371\/journal.pone.0124500","journal-title":"PLoS ONE"},{"key":"3420_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/13607863.2010.501062","volume":"15","author":"P Montejo","year":"2011","unstructured":"Montejo P, Montenegro M, Fernandez MA et al (2011) Subjective memory complaints in the elderly: prevalence and influence of temporal orientation, depression and quality of life in a population-based study in the city of Madrid. Aging Ment Health 15:85\u201396. https:\/\/doi.org\/10.1080\/13607863.2010.501062","journal-title":"Aging Ment Health"},{"key":"3420_CR38","doi-asserted-by":"publisher","first-page":"66S","DOI":"10.1007\/BF02982590","volume":"12","author":"N Coley","year":"2008","unstructured":"Coley N, Ousset PJ, Andrieu S et al (2008) Memory complaints to the general practitioner: data from the GuidAge study. J Nutr Health Aging 12:66S-72S. https:\/\/doi.org\/10.1007\/BF02982590","journal-title":"J Nutr Health Aging"},{"key":"3420_CR39","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S518951","author":"J Yu","year":"2025","unstructured":"Yu J, Chen J, Yang L (2025) Subjective memory complaints: a conceptual analysis. J Multidiscip Healthc. https:\/\/doi.org\/10.2147\/JMDH.S518951","journal-title":"J Multidiscip Healthc"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-026-03420-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03420-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-026-03420-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:21:03Z","timestamp":1782706863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-026-03420-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3420"],"URL":"https:\/\/doi.org\/10.1007\/s40520-026-03420-5","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CK reports research support from Roche Diagnostics for plasma biomarker measurements and receives consultancy fees from Roche Diagnostics Penzberg. M.B. is a member of the Neuroimaging Committee of the EANM. M.B. has received speaker honoraria from Roche, GE Healthcare, Iba, Miltenyi, and Life Molecular Imaging; has advised Life Molecular Imaging, MIAC, Cenos, and GE healthcare; and is currently on the advisory or imaging review boards of AC Immune and ZRO Imaging. GH, DH, M P-H, AH, S\u00dcG and BSR declare that they have no competing financial or non-financial interests. R.P. has received honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, Janssen-Cilag, AstraZeneca, Schwabe, Grifols, Novo Nordisk, GSK, BMS and Tabuk and holds shares of Medotrax GmbH and Vistim Labs Ltd. All authors have reviewed and approved this statement. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of LMU Munich (reference numbers 18\u20130606 and 19\u2013148). All procedures involving human participants were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants prior to study participation. Only individuals capable of providing informed consent were included in the study. All procedures were conducted in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"157"}}